{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.0","value":"3.3"},{"groupId":"OG001","spread":"1.9","value":"3.2"},{"groupId":"OG002","spread":"2.4","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"650"},{"groupId":"OG001","value":"568"},{"groupId":"OG002","value":"82"}],"units":"Participants"}],"description":"Objective 3: To determine the extent to which the primary and secondary prophylaxis of FN in cancer patients is in congruence with the EORTC best practice guidelines and dosing recommendations, and whether this is associated with better outcomes.\n\nPatient risk score (PRS) shows the individual patient risk for FN.The PRS is a sum of eight weighted individual patient risk factors for FN and results in a possible score of 0 to 11 (highest risk for FN). The risk factors were assigned weights based on the level of risk specified by guidelines and SC consensus (age \\> 65 years: 3.0; advanced disease: 1.5; history of FN: 3.0; No antibiotic prophylaxis: 0.5; poor performance/nutritional status: 1.5; female gender: 0.5; Hb\\<12g/dL: 0.5; Renal, CV or liver disease: 0.5).\n\nAdvanced disease: Stage IV or Stage III + prior chemotherapy in metastatic setting; CV: cardiovascular; EORTC: European Organization for Research and Treatment in Cancer; FN: febrile neutropenia","dispersionType":"Standard Deviation","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (all patients).","id":"OG000","title":"EP2006 - All Patients"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (Solid tumor).","id":"OG001","title":"EP2006 - Solid Tumor"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (Hematological tumor).","id":"OG002","title":"EP2006 - Hematological Tumor"}],"paramType":"MEAN","populationDescription":"Patients with chemotherapy with 10-20% risk of FN in the evaluable sample by tumor type","reportingStatus":"POSTED","timeFrame":"Enrollment cycle. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.","title":"Patient Risk Score (PRS) for Patients Receiving Chemotherapy With 10-20% FN Risk by Tumor Type","type":"PRIMARY","unitOfMeasure":"Scores on a scale"}